FRIENDSWOOD, Texas, May 03, 2024--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.
Comprehensive Analysis of Castle Biosciences' First Quarter Financial Performance
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 75.68% and 6.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?